Composite Scheme of Arrangement

SeQuent Scientific Limited (BSE: 512529, NSE: SEQUENT), headquartered in India, operates in Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc. SeQuent currently produces APIs and Animal health formulations in over 100 countries and has more than 1,500 employees.

Investor Relation

Company

Privacy & Policy

Crafted by : Version-Next

Composite Scheme of Arrangement

Complaint Report-NSE

Compliant Report-BSE

No material event impacting the valuation has occurred during the intervening period of filing the scheme documents with Stock Exchange

Declaration from the listed entity on any past defaults of listed debt obligations of the entities forming part of the scheme

Accounting Treatment Certificate format Annexure V

No Objection certificate from lenders with respect to composite scheme of amalgamation

Board Resolution

Compliance Report

Independent Director Report

Post-shareholding of Sequent Scientific Limited

Pre-shareholding of all entities which are part of the Scheme

Joint Valuation Report

Audit Committee Report

Fairness Opinion

Statutory Auditor Certificate on Accounting Treatment

Latest Audited Financials

Composite Scheme Amalgamation

Merger Proposal Investor Presentation – September 27, 2024

Out come of Board meeting- September 26, 2024

Audio Recording of Merger Conference Call – October 01, 2024

Transcript of Merger Conference Call – October 01, 2024

Cost of Acquisition Document

BSE and NSE Publication Intimation

Investor Presentation

Notice of NCLT convened Meeting

Postal Ballot Form

E – voting Instructions

Observation Letter NSE

Observation Letter BSE

Revised Valuation Report

Scheme of Demerger

Board Resolution

Fairness Opinion

Audit Committee Report

Valuation Certificate

Auditors Certificate on Accounting Treatment

Networth Certificate

Compliance Report

Corporate Governance Report

Rationale

Brief Details of companies

Shareholding Pattern

Investor Relation

Company

Privacy & Policy